Is the Wegovy pill as effective as the shot? What the trial data actually shows

The myth: 'a pill will always work less well than an injection'

People assume oral medicines are a weaker version of their injected counterparts, and with older GLP-1 drugs that was largely true. Semaglutide is notoriously difficult to absorb through the gut, stomach acid breaks it down before it reaches the bloodstream. The tablet solves this by pairing semaglutide with an absorption enhancer called SNAC, which effectively shields the molecule long enough for it to cross the stomach lining.

That engineering is good, but it isn't quite as efficient as injecting the drug directly under the skin. The result is a slightly lower average weight loss in the tablet trial versus the injection trial. Around 13.6% average in OASIS 4 against roughly 15% in STEP 1, a real difference, though not a dramatic one. And when researchers looked only at participants who took the tablet consistently and followed the dosing rules carefully, the figure climbed to about 16.6%.

The dosing rules matter more with the tablet than with the pen. You take it first thing in the morning on an empty stomach with a small sip of plain water, then wait at least 30 minutes before any food, coffee, or other medicines. Miss that window and absorption drops significantly. For people who can build that habit, the results look much closer to the injection than the headline averages suggest. You can read more about how this medicine works on our Wegovy pill overview page.

Where the two forms actually differ, beyond the numbers

Effectiveness is one dimension; practicality is another, and the two forms genuinely differ there. The injection is once weekly: you pick a day, store the pen in the fridge, and it becomes a short routine. The tablet is once daily and non-negotiable about timing. Some people find a daily habit easier to sustain; others find it harder than remembering one weekly pen.

Storage is a clear win for the tablet. No refrigeration is needed, which matters for travel and for anyone whose fridge space is already spoken for. The injection pen needs to be kept at 2–8°C and has a limited room-temperature window, always check the patient leaflet for the exact figures rather than relying on a third-party summary.

The side-effect profiles are broadly similar: nausea, digestive discomfort, and fatigue are the most commonly reported with both. In the OASIS 4 trial, around 74% of tablet users reported gastrointestinal effects versus roughly 42% in the placebo group, most were mild to moderate and settled with time. The practical considerations around the tablet are worth understanding before choosing between them. If you're also thinking about how semaglutide tablets compare with earlier oral options, our page on whether semaglutide pills are effective covers the broader picture.

One thing that does not differ: neither form is available without a prescription. A prescriber looks at your health history, current medicines, and BMI before recommending either.

Rybelsus is not the same as the Wegovy tablet, a distinction that trips people up

Rybelsus is also oral semaglutide, but it is licensed for type 2 diabetes at doses of 3mg, 7mg, and 14mg. The Wegovy tablet is licensed for weight management at doses of 1.5mg, 4mg, 9mg, and 25mg. Different licence, different dose ladder, different clinical purpose. Our page comparing Rybelsus and Wegovy goes into this properly if you're seeing both names and feeling confused, and it's a question our prescribers hear most weeks.

The distinction matters because someone researching 'oral semaglutide for weight loss' can easily stumble across Rybelsus information and assume the doses are interchangeable. They are not. The Wegovy weight-loss tablet was approved by the MHRA on 11 June 2026, making the UK the first country in Europe to licence an oral GLP-1 specifically for weight management. Rybelsus predates that approval and serves a different population. If you've seen information about semaglutide tablets and want a broader grounding, our semaglutide tablet guide explains both products and their separate roles.

Who tends to be offered one over the other?

Clinical suitability drives the choice more than personal preference, though preference is a legitimate input. Some people have needle anxiety that makes weekly injections genuinely difficult to sustain; for them the pill may support better long-term adherence even if the average weight loss is modestly lower. Others find a daily first-thing routine harder to fit in, think about how your morning actually runs before deciding it sounds easy.

BMI thresholds apply to both: the tablet is licensed for adults with a BMI of 30 or above, or 27–29.9 with a weight-related health condition. The injection carries similar criteria. Neither form is recommended during pregnancy, breastfeeding, or while actively trying to conceive. The medicines are also not licensed for under-18s. Our page on Wegovy tablets for women covers some of the specific considerations that come up, including contraception, there is a separate question about whether semaglutide affects the oral contraceptive pill, which we address on our page about Wegovy and the pill.

Cost context is relevant too, and you can find a balanced explanation of what private weight-loss treatment typically involves on our weight-loss treatment overview. The right choice between tablet and injection is ultimately made with a prescriber, not by a comparison page. If you'd like that conversation, checking your eligibility with our team is a good place to start.